CANCER OF UNKNOWN PRIMARY SITE
Clinical trials for CANCER OF UNKNOWN PRIMARY SITE explained in plain language.
Never miss a new study
Get alerted when new CANCER OF UNKNOWN PRIMARY SITE trials appear
Sign up with your email to follow new studies for CANCER OF UNKNOWN PRIMARY SITE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for mysterious cancers: immune drug trial shows promise
Disease control CompletedThis study tested an immunotherapy drug called sintilimab for patients with advanced cancer of unknown primary origin (CUP), a rare and difficult-to-treat cancer where the original site is unknown. The trial enrolled 10 patients whose cancer had progressed after standard chemothe…
Matched conditions: CANCER OF UNKNOWN PRIMARY SITE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Genetic testing vs standard chemo: which works better for mysterious cancers?
Disease control CompletedThis study tested whether personalized cancer treatment based on genetic testing works better than standard chemotherapy for cancers where doctors can't find the original source. It involved 529 patients whose cancer had responded to initial chemotherapy. Researchers compared how…
Matched conditions: CANCER OF UNKNOWN PRIMARY SITE
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
New hope for mysterious cancers: immune therapy trial shows promise
Disease control CompletedThis study tested whether the immunotherapy drug pembrolizumab could help control cancer of unknown primary, where doctors can't identify where the cancer started. The trial included 35 patients in two groups: those who had already tried chemotherapy and those receiving it as the…
Matched conditions: CANCER OF UNKNOWN PRIMARY SITE
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Mar 06, 2026 15:37 UTC